Klinická farmakologie a farmacie – 2/2020

www.klinickafarmakologie.cz  / Klin Farmakol Farm 2020; 34(2): 63–69 / KLINICKÁ FARMAKOLOGIE A FARMACIE 69 PŘEHLEDOVÉ ČLÁNKY Vliv genetických a epigenetických faktorů jako kovariátů snášenlivosti a léčebné odpovědi na olanzapin v terapii psychotických onemocnění J. Olanzapine‑induced weight gain is associated with the­ -759C/T and-697G/C polymorphisms of the HTR2C gene. Pharmacogenomics Journal 2009; 9: 234–241. 61. Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN. Mesolimbic dopamine D3 receptors and use of an­ tipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 1997; 54: 225–232. 62. Reynolds G, Yao Z, Zhang X, Sun J, Zhang Z. Pharmaco­ genetics of treatment in first‑episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. European Neu­ ropsychopharmacology 2005; 15: 143–151. 63. Adams D, Close S, Farmen M, Downing A, Breier A, Hous­ ton J. Dopamine receptor D3 genotype association with grea­ ter acute positive symptom remission with olanzapine the­ rapy in predominately caucasian patients with chronic schi­ zophrenia or schizoaffective. Human Psychopharmacology­ ‑Clinical and Experimental 2008; 23: 267–274. 64. ReynoldsGP,TemplemanLA,ZhangZJ.Theroleof5-HT2Cre­ ceptorpolymorphisms inthepharmacogeneticsofantipsychotic drug treatment. Progress in Neuro‑Psychopharmacology&Bio­ logical Psychiatry 2005; 29: 1021–1028. 65. Samanaite R, Gillespie A, Sendt KV, McQueen G, MacCabe JH, Egerton A. Biological Predictors of Clozapine Response: A Systematic Review. Front Psychiatry 2018; 9: 327. 66. Zhang JP, Malhotra AK. Recent Progress in Pharmaco­ genomics of Antipsychotic Drug Response. Curr Psychiat­ ry Rep 2018; 20: 24. 67. Miller CA, Sweatt JD. Covalent modification of DNA regu­ lates memory formation. Neuron 2007; 53: 857–869. 68. Miller CA, Gavin CF, White JA, Parrish RR, Honasoge A, Yan­ cey CR, Rivera IM, et al. Cortical DNA methylation maintains remote memory. Nature Neuroscience 2010; 13: 664–666. 69. Ghadirivasfi M, Nohesara S, Ahmadkhaniha HR, Eskanda­ ri MR, Mostafavi S, Thiagalingam S, Abdolmaleky HM. Hypo­ methylation of the Serotonin Receptor Type-2 AGene (HTR2A) at T102C Polymorphic Site in DNA Derived From the Saliva of Patients With Schizophrenia and Bipolar Disorder. American Journal of Medical Genetics Part B‑Neuropsychiatric Gene­ tics 2011; 156 B: 536–545. 70. Kebir O, Chaumette B, Fatjó‑Vilas M, Ambalavanan A, Ra­ moz N, Xiong L, Mouaffak F, et al. Family‑based association study of common variants, rare mutation study and epistatic interaction detection in HDAC genes in schizophrenia. Schi­ zophr Res 2014; 160: 97–103. 71. Levenson JM, O‘Riordan KJ, Brown KD, Trinh MA, Molfese DL, Sweatt JD. Regulation of histone acetylation during me­ mory formation in the hippocampus. Journal of Biological Chemistry 2004; 279: 40545–40559. 72. Peleg S, Sananbenesi F, Zovoilis A, Burkhardt S, Bahari­ ‑Javan S, Agis‑Balboa RC, Cota P, et al. Altered Histone Ace­ tylation Is Associated with Age‑Dependent Memory Impair­ ment in Mice. Science 2010; 328: 753–756. 73. Alarcon JM, Malleret G, Touzani K, Vronskaya S, Ishii S, Kandel ER, Barco A. Chromatin acetylation, memory, and LTP are impai­ red inCBP+/-mice:Amodelforthecognitivedeficit inRubinstein­ ‑Taybisyndromeand itsamelioration.Neuron2004;42:947–959. 74. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multip­ le roles of HDAC inhibition in neurodegenerative conditions. Trends in Neurosciences 2009; 32: 591–601. 75. Weïwer M, Lewis MC, Wagner FF, Holson EB. Thera­ peutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia. Future Med Chem 2013; 5: 1491–1508. 76. Kebir O, Chaumette B, Fatjo‑Vilas M, Ambalavanan A, Ra­ moz N, Xiong L, Mouaffak F, et al. Family‑based association study of common variants, raremutation study and epistatic interaction detection in HDAC genes in schizophrenia. Schi­ zophrenia Research 2014; 160: 97–103. 77. Kim T, Park JK, Kim HJ, Chung JH, Kim JW. Association of histone deacetylase genes with schizophrenia in Korean po­ pulation. Psychiatry Res 2010; 178: 266–269. 78. Brousse G, Meary A, Blanc O, Lancon C, Llorca P, Leboyer M. Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia. Psychiatry Research 2010; 179: 12–18. 79. Cheah SY, Lawford BR, Young RM, Morris CP, Voisey J. mRNA Expression and DNA Methylation Analysis of Seroto­ nin Receptor 2 A(HTR2A) in the Human Schizophrenic Brain. Genes (Basel) 2017; 8. 80. Ghadirivasfi M, Nohesara S, Ahmadkhaniha HR, Eskanda­ ri MR, Mostafavi S, Thiagalingam S, Abdolmaleky HM. Hypo­ methylation of the serotonin receptor type-2 AGene (HTR2A) at T102C polymorphic site in DNA derived from the saliva of patients with schizophrenia and bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2011; 156 B: 536–545. 81. Dazzan P. Neuroimaging biomarkers to predict treatment response in schizophrenia. European Neuropsychopharma­ cology 2016; 26: S140-S140. 82. Dazzan P. Neuroimaging biomarkers to predict tre­ atment response in schizophrenia: the end of 30 years of solitude? Dialogues in Clinical Neuroscience 2014; 16: 491–503.